Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.

Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.

Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.

Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: The use of HETE derivatives to treat dry eye conditions associated with refractive surgery is disclosed.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions contain a mast cell stabilizing disulfide derivative as an active ingredient.

Abstract: A topical ophthalmic composition for the treatment of dry eye in humans, comprising one or more histamine H2 agonists, is disclosed.

Abstract: Composition and methods for treating ocular allergic reactions are disclosed. In particular, the invention is directed to compounds which inhibit human conjunctival mast cell degranulation.

Abstract: Compositions containing histamine H2 agonists and methods of use for treating allergy and inflammation of the eye are disclosed.

Abstract: Compositions containing a HETE derivative and methods of use for treating dry eye are disclosed.

Abstract: By allowing the mast cell enriched population of human conjunctival tissue cells to incubate for a minimum of about forty (40) hours post enzymatic digestion, the treatment window between spontaneous histamine release and anti-human IgE stimulated histamine release is increased. Culturing the human conjunctival tissue mast cells decreases the spontaneous release of histamine and increases the anti-IgE stimulated histamine release, greater than ten fold over spontaneous, at time points over forty (40) hours. This treatment window is sufficient to detect a compound's stabilizing or anti-allergic activity.

Abstract: A cylinder apparatus includes a piston and a cylinder tube including a first end and a second end. The cylinder tube is formed to include a central bore extending from the first end to the second end for receiving the piston therein and a second bore extending from the first end to the second end spaced apart from the central bore. The cylinder apparatus also includes a first end cap coupled to the first end of the tube and a second end cap coupled to the second end of the tube. The second end cap is formed to include a first port in communication with the central bore of the tube and a second port in communication with the second bore. First end cap and second end cap have similar configurations and use substantially identical seals. Therefore, the semi-finished parts of the present invention have substantially identical configurations, regardless of the specific embodiment selected for a particular use.

Abstract: An apparatus for the thermal-catalytic abatement of hydrocarbons, carbon monoxide, nitrogen oxides and particulates from effluent gas streams. The apparatus has a preheat section wherein the effluent is heated to 400.degree.-1000.degree. F by hot combustion gases. The effluent and combustion gases are directed by a baffle through a filter where combustible particulates are incinerated and noncombustible particulates are collected. The baffle followed by a diffuser cone, axially located on the filter, intimately mixes the effluent with the combustion gases so as to provide uniform flow and temperature distribution of the mixed gases across the filter. The filtered gases then pass through a catalytic reactor section containing a catalyst, preferably catalyst-coated ceramic honeycombs. In the presence of the catalysts the hydrocarbons and carbon monoxide in the heated gas stream are oxidized to carbon dioxide and water and the nitrogen oxides are reduced.